[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"lung-diseases-obstructive\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:lung-diseases-obstructive":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,46,74,108],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100466247","thermotherapy-against-persistent-bacterial-lung-infections-100466247",false,"NCT05351242","THERMotherapy Against Persistent Bacterial LUNG Infections","Thermotherapy Against Persistent Bacterial LUNG Infections","THERMA-LUNG","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Competent and capable\n* FEV1\\>1,0 L\n* Have had a positive culture from sputum or BAL min. 2 times in the last 24 months for bacteria of the species: Pseudomonas aeruginosa, Stenotrophomonas maltophilia, Staphylococcus aureus, Haemophilus influenzae, Achromobacter xylosoxidans, Klebsiella oxytoca or Klebsiella pneumoniae. In addition, min. 1 positive culture after treatment with antibiotics\n* Willing to go to a sauna (min. temperature of 85℃ for at least 7 minutes) four times weekly for six months or avoid going to a sauna for six months\n\nExclusion Criteria:\n\n* Allergy to lidocaine and\u002For midazolam\n* Contraindications to bronchoscopy\n* Previous severe laryngospasm (intubation requiring)\n* Pregnancy\u002Fbreastfeeding\n* Severe linguistic problems or inability to give informed consent\n* Severe mental illness that is not controlled with medication. NB: Patients with controlled mental illness can be included and will be asked on an equal footing as others","ALL","18 Years",{"count":20,"type":21},150,"ESTIMATED","INTERVENTIONAL",[24],"NA","The aim of this study is to determine whether an intervention with frequent thermotherapy will be able to reduce the amount of colonizing bacteria in the bronchoalveolar lavage sample and eradicate the colonizing bacteria.",[27,28,29,30,31,32],"Lung Diseases, Obstructive","Bronchiectasis","Asthma","Copd","Chronic Obstructive Pulmonary Disease","Chronic Lung Infections","NOT_YET_RECRUITING","2026-06-15",{"date":36,"type":37},"2026-06-17","ACTUAL",{"date":39,"type":21},"2026-10-01",{"date":41,"type":21},"2029-12-31",{"name":43,"class":44},"Chronic Obstructive Pulmonary Disease Trial Network, Denmark","OTHER",1,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":52,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":17,"minAge":54,"maxAge":4,"enrollmentInfo":55,"targetDuration":4,"studyType":57,"phases":4,"briefSummary":58,"conditions":59,"keywords":4,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":45},"100504917","cough-capture-as-a-portal-into-the-lung-100504917","NCT05854563","Cough Capture as a Portal Into the Lung","Genetics of Lung Disease (Exhaled Breath DNA Methylation in Lung Carcinogenesis)","CC1","Inclusion Criteria:\n\n* Age: minimum age of 21 years\n* Gender: Male and Female adults\n* Ethnicity: All ethnic groups and races\n* Subjects undergoing bronchoscopy for diagnostic purposes or therapy\n* Subjects without a known diagnosis of lung cancer who are not scheduled for lung tissue collection procedures\n* Subjects with a known or suspected diagnosis of asthma or COPD and are scheduled for a visit at Montefiore Asthma or COPD Center and individual practices, and\u002For in-hospital with exacerbation\n\nExclusion Criteria:\n\n* Bleeding diathesis or known coagulopathy precluding clinically indicated biopsy (e.g., INR\\>1.3, PTTr\\>1.3), thrombocytopenia \\\u003C50,000, uremia with serum creatinine \\>3.0\n* Unstable angina\n* Recent myocardial infarction (within 3 months),\n* Uncontrolled congestive heart failure or severe pulmonary hypertension (mean PAP\\>75 mmHg)","21 Years",{"count":56,"type":21},2000,"OBSERVATIONAL","The lung is a privileged organ; blood does not reflect most lung processes well, if at all. Therefore, for population scale diagnostics, the investigator team is developing non-invasive portals to the lung, for eventual early detection\u002Frisk assessment and diagnostic purposes. However, large macromolecules are not likely suspended nor readily detected in the breath. In particular, genomic DNA in the breath condensate (EBC) is very sparse, and where present, generally highly fragmented, not readily amenable to sequencing based assessments of DNA somatic mutation burden or distribution. Because gDNA (and protein) is challenging to obtain non-invasively from EBC, the study team considered alternative surrogate lower airway specimens. Cough capture is rarely done, and the investigator team is in the process of optimizing its collection. Importantly, the team will be evaluating how much of coughed material is from saliva contamination. Additionally, analyzing material that is target captured by capturing deep lung extracellular vesicles (EVs) using immobilized CCSP\u002FSFTPC antibodies targeting EVs from distal bronchiole Club and alveolar type 2 cells could circumvent the mouth contamination problem, leaving a non-invasive portal to the deep lung suitable for large molecules, and in turn suitable for myriad epidemiologic and clinical applications.\n\nThe investigator team proposes (Aim 1) to pursue optimizing cough collection, and testing the efficacy and practicality of partitioning cough specimen for deep-lung specific extra-cellular vesicles (EVs). This cough specimen will be compared to that from invasively collected deep lung samples BAL\u002Fbronchial brushings, and to the potential contaminating mouth rinse, all from the same individuals. (Aim 2) The study team initially proposes to examine these cough specimens for somatic mutations by SMM bulk sequencing for single nucleotide variation, developed in the Vijg\u002FMaslov labs. Finally, the investigator team will (Aim 3) test all airway specimens (cough, mouthwash and BAL) for lung surrogacy of cough, using proteins known to be specific for lung, as opposed to oral cavity\u002Fsaliva, in the Sidoli\u002Fproteomics core.\n\nThe investigator team envisions that the translational impact of non-invasively obtained DNA or protein markers could allow for more rapid acute clinical diagnoses, and facilitate precision prevention and\u002For early detection of many acute and chronic respiratory disorders, including lung cancer, asthma and COPD, acute and chronic infectious diseases, and indeed systemic disorders of inflammation and metabolism.",[60,61,27,62,63],"Lung Diseases","Lung Cancer","Lung Diseases, Interstitial","Lung Inflammation","RECRUITING","2026-01-12",{"date":67,"type":37},"2026-01-13",{"date":69,"type":37},"2023-03-28",{"date":71,"type":21},"2027-06",{"name":73,"class":44},"Albert Einstein College of Medicine",{"id":75,"slug":76,"hasResults":11,"nctId":77,"briefTitle":78,"officialTitle":79,"acronym":4,"eligibilityCriteria":80,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":81,"targetDuration":4,"studyType":22,"phases":83,"briefSummary":84,"conditions":85,"keywords":88,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":99,"lastUpdatePostDateStruct":100,"startDateStruct":102,"completionDateStruct":104,"leadSponsor":106,"locationsCount":45},"100515581","efficacy-of-efa-in-acquired-brain-injury-100515581","NCT05993364","Efficacy of EFA in Acquired Brain Injury","Role of Expiratory Flow Acceleration in the Management of Bronchial Secrections in Severe Acquired Brain Injury: a Pilot Randomized Controlled Study","Inclusion Criteria:\n\n* Age higher than 18 years old;\n* Hospitalization after diagnosis of Acquired Brain Injury (both traumatic and vascular)\n* Levels of Cognitive Functioning Scale (LCFS) score between 1and 5;\n* Presence of spontaneous breathing, at least during the day\n\nExclusion Criteria:\n\n* Need of mechanical ventilation for more than 12 hours a day;\n* Presence of tracheal stoma not properly healed after the removal of the tracheal cannula.",{"count":82,"type":21},20,[24],"Acquired brain injury (ABI) is one of the biggest cause of death and disability in the world. Patients with ABI often have difficulties with swallow and breath.\n\nThe study purpose is to evaluate if the Expiratory Flow Accelerator (EFA) technology has positive effects on the respiratory and swallowing function in patients with acquired brain injury (ABI). Researchers recruit patients at Centro Ettore Spalenza-Fondazione Don Carlo Gnocchi in Rovato, Italy.\n\nTo partecipate, patients should satisfy certain eligibility criteria; they will not be enrolled if they satisfy exclusion criteria.\n\nIf a patient can be recruited, researchers conduct the baseline assessment lasting 1 one week. After that, the patient will be randomized to the study or control group. If the patient is in the control group, he will receive a traditional rehabilitation treatment. Otherwise, the patient will receive an additional treatment with the EFA device.\n\nResearchers will assess again the patient (with the same procedures of baseline assessment) after 8 weeks of treatment. They want to see if the EFA device could help patients with ABI to improve their health conditions.",[86,87,27],"Acquired Brain Injury","Comparative Effectiveness Research",[89,90,91,92,93,94,95,96,97,86,98],"Expiratory Flow Accelerator","Tracheobronchial secretions","Tracheobronchial clearance","Airways clearance","Pulmonary infections","Pulmonary obstruction","Decannulation","Tracheal cannula","Effectiveness","Controlled study","2024-08-08",{"date":101,"type":37},"2024-08-09",{"date":103,"type":37},"2024-02-19",{"date":105,"type":21},"2025-12",{"name":107,"class":44},"Fondazione Don Carlo Gnocchi Onlus",{"id":109,"slug":110,"hasResults":11,"nctId":111,"briefTitle":112,"officialTitle":113,"acronym":4,"eligibilityCriteria":114,"healthyVolunteers":11,"sex":17,"minAge":115,"maxAge":4,"enrollmentInfo":116,"targetDuration":4,"studyType":22,"phases":118,"briefSummary":119,"conditions":120,"keywords":124,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":130,"lastUpdatePostDateStruct":131,"startDateStruct":133,"completionDateStruct":135,"leadSponsor":137,"locationsCount":45},"100461306","antibiotic-stewardship-in-aecopd-through-crp-guided-management-100461306","NCT05286918","Antibiotic Stewardship in AECOPD Through CRP-Guided Management","Antibiotic Stewardship Through CRP-guided Antibiotic Treatment for Patients With Acute Exacerbation of Chronic Obstructive Pulmonary Disease (AECOPD)","Inclusion Criteria:\n\n1. Being diagnosed with active AECOPD (AECOPD is defined as an event in the natural course of a disease characterized by a change in baseline dyspnoea, cough, and\u002For sputum that is beyond the normal day-to-day variations with acute onset, which may warrant a change in regular medication in patients with underlying COPD).\n2. Known COPD in their medical records.\n3. Age 40 years or older.\n4. Able to provide informed consent in Cantonese, Mandarin, or English\n5. Able to complete the questionnaires during the study period (i.e. 6 months after randomisation)\n\nExclusion Criteria:\n\nPatients will be excluded if any ONE of the following are present:\n\n1. Pre-treatment with systemic corticosteroids for the present exacerbation.\n2. Pre-treatment with any antibiotics for the present exacerbation, any concurrent infection or prophylaxis.\n3. Known clinical stroke in past 6 months\n4. Patients with high suspicion of active AECOPD mimics:\n\n   1. Pneumonia\n   2. Congestive heart failure\n   3. Bronchiectasis\n   4. Pulmonary embolism\n   5. Pneumothorax\n   6. Atrial fibrillation \u002F flutter\n5. Lung comorbidities:\n\n   1. Cystic fibrosis\n   2. Tuberculosis\n   3. Unresolved lung malignancy\n6. Progression or new radiographic abnormalities on the chest X-ray.\n7. Immunodeficiency disorders such as AIDS, humoral immune defect, ciliary dysfunction etc., and the use of immunosuppressive drugs for more than 28 days.\n8. Active inflammatory condition (e.g. flare up of rheumatoid arthritis, gout or polymyalgia rheumatica) or concurrent infection at another site (e.g. UTI, cellulitis) that is likely to produce a systemic response\n9. Currently pregnant\n10. NEWS2 score of ≥3","40 Years",{"count":117,"type":21},1184,[24],"Objectives:\n\nTo determine whether CRP-guided antibiotic treatment for managing AECOPD in adult patients attending Emergency Departments leads to reduced antibiotic duration, without non-inferior COPD health status with usual care.\n\nHypothesis to be tested:\n\n(i) The antibiotic duration in AECOPD patients will be significantly lower for CRP-guided antibiotic discontinuation than usual care; and (ii) COPD health status as measured by the Clinical COPD Questionnaire has no statistically significant difference between two groups.\n\nDesign and subjects:\n\nMulti-center, single-blind, open-label, randomized, combined superiority (antibiotic duration) and non-inferiority (COPD health status) trial in 1,184 adult AECOPD patients presented to A\\&E.\n\nInstruments:\n\nClinical COPD Questionnaire and EuroQol-5D\n\nInterventions:\n\nBoth intervention and control groups follow usual care with GOLD strategy. The intervention group will be recommended to test for serum CRP daily. Antibiotic prescription is considered when CRP \\>5mg\u002FdL. Once CRP has declined to \\\u003C5mg\u002FdL and the patient was afebrile for past 48 hours, antibiotic discontinuation will be considered.\n\nCommunication with Receiving Ward Staffs:\n\nParticipants in the study may transfer to another departments after treatment\u002F care in A\\&E. The following communication would be conducted:\n\n* A handover note that informs the receiving ward staffs about patients' enrolment to the trial, group assignment, and previous treatments given in A\\&E. The note would also suggest the investigations for the receiving ward staffs.\n* Telephone handover about intervention group and investigations of the study, and treatments given in A\\&E to ward.\n\nMain outcome measures:\n\nThe antibiotic duration (total number of antibiotic days) within 28 days and recovery in terms of COPD health status (Clinical COPD Questionnaire total scores) within 14 days from randomisation.\n\nData analysis:\n\nIntention-to-treat and cost-effectiveness analyses will be performed. The outcome assessors and data analysts will be blinded to group allocation.\n\nExpected results:\n\nThe intervention group will exhibit reduction in antibiotic duration at 4-weeks, without negatively impacting on COPD health status, compared with the control group.",[121,60,27,122,123],"Acute Exacerbation of COPD","Pulmonary Disease, Chronic Obstructive","Respiratory Tract Disease",[125,126,127,128,129],"COPD","Antibiotics","C-Reactive Protein","Antibiotic stewardship","Emergency Department","2022-05-16",{"date":132,"type":37},"2022-05-23",{"date":134,"type":21},"2022-09-01",{"date":136,"type":21},"2026-08-31",{"name":138,"class":44},"The University of Hong Kong"]